The benchmark S&P 500 index retains breaking new data thanks largely to a handful of shares on the high. Fortunately for income-seeking traders, there are some extremely dependable dividend shares on the market that have not been swept up within the pleasure.Shares of Pfizer (NYSE: PFE), Ares Capital (NASDAQ: ARCC), and Bristol Myers Squibb (NYSE: BMY) are moderately valued, with a mean dividend yield of about 7% at latest costs. Furthermore, there is a good probability that each one three can meet their commitments and proceed elevating them for a few years to come back.PfizerAt latest costs, Pfizer affords a juicy 6% yield, supported by revenue from gross sales of modern new medicine. The corporate has raised its dividend payout for 15 consecutive years, and it appears to be like able to sustaining this streak for at the very least one other decade.Pfizer reinvested a few of the monumental revenue its COVID-19 merchandise generated into new sources of income that may preserve its needle shifting in the best path. For instance, the $43 billion acquisition of Seagen in 2023 gave it entry to 4 commercial-stage most cancers medicine, together with Padcev.Final December, the Meals and Drug Administration (FDA) authorized Padcev for the remedy of newly recognized sufferers with advanced-stage bladder most cancers. New sufferers have a tendency to remain on remedy for much longer than people who’ve already relapsed, so this label enlargement may add billions to Pfizer’s high line within the years forward.Along with Padcev’s label enlargement, the FDA additionally authorized a file 9 new medicine from Pfizer final 12 months. With loads of new income sources, one other decade of regular dividend raises appears possible.Ares CapitalAres Capital is a enterprise improvement firm (BDC), which implies it has to distribute almost all its income to traders as a dividend. This BDC’s dividend hasn’t risen in a straight line, however it’s up by 26% over the previous decade.At latest costs, the inventory affords an eye-popping 9.2% yield and a superb probability to see considerably extra once you’re able to retire.For many years, large American banks have been more and more hesitant about lending to all however the largest companies. Because of this, Ares Capital and its BDC friends can at all times discover midsize corporations keen to simply accept comparatively high-interest loans.Ares Capital collected mortgage funds from 510 completely different corporations within the first quarter. With an funding portfolio value $23.1 billion, it is the biggest publicly traded BDC. Which means it has heaps of relationships with mid-market companies and their non-public fairness sponsors.Story continuesWith loads of potential debtors to select from, Ares Capital’s underwriting division can concentrate on these more than likely to repay their money owed. On the finish of March, simply 0.7% of investments had been on non-accrual standing.Bristol Myers SquibbBristol Myers Squibb is one other massive drugmaker, with a 15-year consecutive annual dividend-raising streak. At latest costs, the pharma inventory affords a giant 5.9% dividend yield and a very good probability for additional payout raises.Shares of Bristol Myers Squibb are down largely as a result of the corporate frightened traders with a drastically diminished earnings outlook for 2024. In February, administration informed traders it might earn between $7.10 and $7.40 per share this 12 months. In April, the corporate slashed its 2024 earnings estimate to a spread between $0.40 and $0.70 per share to account for $12.9 billion value of in-process analysis and improvement bills related to latest acquisitions.Within the first quarter, Bristol Myers Squibb closed out acquisitions of Karuna Therapeutics, Mirati Therapeutics, and RayzeBio. Accounting for the acquisitions early is uncommon, but it surely is not a purpose to keep away from the inventory.Within the first quarter, Bristol Myers Squibb’s portfolio of extra just lately launched medicine grew gross sales by 11% if we ignore the destructive results of a stronger greenback. With potential contributions from latest acquisitions, there is a good probability this drugmaker will preserve elevating its payout for an additional 15 years. Including some shares to an income-generating portfolio now appears to be like like a sensible transfer.Do you have to make investments $1,000 in Pfizer proper now?Before you purchase inventory in Pfizer, think about this:The Motley Idiot Inventory Advisor analyst workforce simply recognized what they imagine are the 10 greatest shares for traders to purchase now… and Pfizer wasn’t one in all them. The ten shares that made the reduce may produce monster returns within the coming years.Think about when Nvidia made this listing on April 15, 2005… when you invested $1,000 on the time of our suggestion, you’d have $786,046!*Inventory Advisor offers traders with an easy-to-follow blueprint for fulfillment, together with steerage on constructing a portfolio, common updates from analysts, and two new inventory picks every month. The Inventory Advisor service has greater than quadrupled the return of S&P 500 since 2002*.See the ten shares »*Inventory Advisor returns as of July 2, 2024Cory Renauer has positions in Ares Capital. The Motley Idiot has positions in and recommends Bristol Myers Squibb and Pfizer. The Motley Idiot has a disclosure coverage.3 Dependable Dividend Shares With Yields Above 5% You Can Purchase With $100 in July was initially revealed by The Motley Idiot